Methods of treating dementia associated with Alzheimer's disease with protective protein/cathepsin A (PPCA)
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo
Life of this patent
Estimating the term…
Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo
Estimating the term…
Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
A method of treating dementia associated with Alzheimer's disease in a human subject comprising administering to the human subject a therapeutically effective amount of a composition comprising a recombinant viral vector encoding a Protective Protein/Cathepsin A (PPCA) polypeptide.
Dependencies are inferred from the claim text.